Blu Label Unlimited Group (BLU) Trading update summary
Event summary combining transcript, slides, and related documents.
Trading update summary
13 Aug, 2026Earnings performance
Basic, headline, and core headline earnings per share for the year ended 31 May 2024 are expected to increase by more than 20% compared to the previous year.
Earnings per share are projected to rise from 30.48 cents to between 71.88 and 73.10 cents, a 136%–140% increase.
Headline earnings per share are expected to increase from 41.97 cents to between 72.80 and 74.48 cents, a 73%–77% rise.
Core headline earnings per share are anticipated to grow from 45.55 cents to between 75.17 and 76.99 cents, a 65%–69% increase.
Core headline earnings for the year reached R679 million, up from R402 million in the prior year.
Impact of Cell C recapitalisation
Excluding Cell C recapitalisation effects, core headline earnings declined by R312 million (34%) from R925 million to R613 million.
Core headline earnings per share, excluding these effects, dropped by 34% from 104.83 cents to 68.66 cents.
Earnings per share and headline earnings per share, excluding Cell C impacts, declined by 35% to 65.07 cents and 66.22 cents, respectively.
Additional information
The financial information provided has not been reviewed or audited by external auditors.
Latest events from Blu Label Unlimited Group
- AGM approved key resolutions, addressed diversity, ESG, and Cell C governance, with most motions passed.BLU
AGM 2024 - Significant declines in earnings expected due to Cell C restructuring and listing impacts.BLU
Trading update - Normalized revenue ZAR 9.4bn, EBITDA ZAR 923m, core headline earnings ZAR 681m, dividend and buyback.BLU
H2 2026 - Earnings per share are expected to rise by over 20% for the year ended 31 May 2025.BLU
Trading update - Earnings per share to fall over 20%, impacted by Cell C restructuring and related losses.BLU
Trading update - Gross revenue up 16% to ZAR 89.3bn, but core HEPS down 34% amid challenging conditions.BLU
H2 2024 - Gross revenue up 8% to R47.4bn, margins improved, but EBITDA fell on higher finance costs.BLU
H1 2025 - Profit and margin growth accelerated, led by digital innovation and Cell C's operational turnaround.BLU
H2 2025 - Cell C restructuring and 11% revenue growth enabled dividend resumption and strong cash flow.BLU
H1 2026